Nossos produtos são clinicamente testados por terceiros
Leia Mais
×
Experimente resultados com confiança
Se a Hairgenetix não entregar resultados em 4 meses, obtenha um reembolso total em apenas 3 passos simples.
Trusted by hundreds e rated
Com uma classificação 'Excelente' de 4,6 estrelas, baseada em mais de 1.200 avaliações, a confiança dos nossos clientes no Hairgenetix reflete os resultados notáveis que você pode alcançar com nossos produtos de crescimento capilar.
Nossos produtos são clinicamente testados por terceiros
Em um ensaio clínico de 150 dias envolvendo 30 homens e mulheres de 18 a 65 anos com diversos tipos de queda de cabelo, o sérum Hairgenetix alcançou uma redução clinicamente comprovada de 93% na queda de cabelo.
Estudo AHK-Cu sobre Crescimento de Folículos Capilares (2007) — Resumo
Publicado por Hyun Keol Pyo, Chong Hyun Won, Kyu Han Kim et al. em 05 de March de 2026
Key Findings at a Glance
The peptídeo de cobre AHK-Cu made human folículo capilars grow significativamente longer in laboratory conditions (p < 0.001). It boosted o proliferation of dermal papilla cells — o "command centre" que tells hair to grow (p < 0.001). It reduced o cell death enzyme caspase-3 by 42.7% e o self-destruct marker PARP by 77.5% (both p < 0.05). It shifted o Bcl-2/Bax survival balance toward cell protection (p < 0.05). Effects were seen at extremely low concentrations (10-12 to 10-9 M), but higher concentrations actually inhibited growth — demonstrating a precise dose-response relationship. This is o foundational laboratory study que established peptídeo de cobres as a viable crescimento capilar ingredient.
Research Evidence Summary
Condition
Hair follicle growth stimulation e dermal papilla cell survival
This article é um plain-language summary of a peer-reviewed scientific study. It is intended to make pesquisa clínica more accessible e is not medical advice. Always consult a qualified healthcare professional antes starting any new tratamento. The original study was conducted independently at Seoul National University e is not affiliated com Hairgenetix.
Reviewed by: Esther Bodde — Cosmetic & Medical Doctor (MD)
Why This Research Matters
If você são experiencing queda de cabelo, você have probably come across peptídeo de cobres as a potential tratamento. But does o science actually support them? This 2007 study de Seoul National University is o cornerstone of peptídeo de cobre hair research — it was o first to demonstrate, using real human folículo capilars, que a specific peptídeo de cobre called AHK-Cu can diretamente stimulate crescimento capilar at o cellular level.
Before este study, researchers already knew que peptídeo de cobres could stimulate skin fibroblasts (the cells que produce collagen) e boost vascular endothelial growth factor (VEGF) — a molecule que melhora blood supply. What they did not know was whether peptídeo de cobres could also affect o specialised cells inside folículo capilars. This study answered que question com a clear yes — e mapped o specific biological pathways involved.
The team at Seoul National University's Department of Dermatology took a two-pronged approach to test whether o peptídeo de cobre AHK-Cu affects crescimento capilar:
1. Testing on real folículo capilars (ex vivo organ culture)
They collected folículo capilars de o occipital (back) couro cabeludo region of 10 healthy volunteers aged 20–35. A total of 240 folículo capilars were isolated e placed in controlled laboratory conditions (Williams' E Medium at 37°C). Follicles were treated com AHK-Cu at concentrations ranging de 10-13 M to 10-7 M (covering six orders of magnitude), com 30 follicles per concentration group. After 12 days, o researchers measured how much each follicle had grown compared to vehicle-treated controls.
2. Testing on follicle command cells (in vitro cell culture)
They isolated dermal papilla cells (DPCs) de human folículo capilars e grew them in culture dishes. These cells sit at o base of each folículo capilar e act as o "command centre" que signals o hair to grow. Using o MTT assay (a standard test para cell viability), they measured whether AHK-Cu made these cells multiply faster. They also ran flow cytometry (Annexin V/PI staining) e western blot analysis to measure specific survival e death markers: Bcl-2, Bax, caspase-3, e PARP.
What Is an Ex Vivo Study?
An ex vivo study tests living tissue que has been taken de o body e maintained in laboratory conditions. Unlike a pure cell culture (where individual cells grow in a dish), ex vivo organ culture preserves o complete tissue structure — in este case, whole folículo capilars com all their cell types intact. This is considered more realistic than pure in vitro testing because o natural architecture e cell-to-cell communication is maintained.
Ex vivo studies sit between test-tube experiments e full clinical trials on o evidence scale. They provide strong proof que a compound has a direct biological effect on o target tissue, but they cannot tell us how que compound will behave when applied to human skin (where absorption, distribution, e metabolism add complexity). This is why ex vivo findings need to be confirmed in human trials — which subsequent studies like the 2016 GHK peptide clinical trial e the 2021 copper tripeptide serum trial have done.
AHK-Cu at concentrations between 10-12 e 10-9 M stimulated measurable folículo capilar elongation over 12 days. The treated follicles physically grew more than o untreated controls, com o effect reaching high statistical significance. Crucially, este worked at extremely low concentrations — picomolar to nanomolar — suggesting high biological potency.
Higher concentrations inhibited growth — a biphasic response
At 10-8 M, follicle elongation was inhibited by 14.8 ± 1.2% (2.3 ± 0.18 mm). At 10-7 M, inhibition reached 81.5 ± 40.8% (only 0.5 ± 0.25 mm of growth). This biphasic dose-response demonstrates que "more is not better" — there is an optimal concentration window para peptídeo de cobre efficacy.
The MTT assay confirmed que DPCs treated com AHK-Cu at 10-12 to 10-9 M proliferated at a significativamente higher rate than untreated cells. More dermal papilla cells means a stronger growth signal being sent to o folículo capilar. At 10-8 M, no proliferative effect was observed — consistent com o follicle resultados.
Cell death enzyme caspase-3 reduced by 42.7% (p < 0.05)
After 72 hours of tratamento com 10-9 M AHK-Cu, o levels of cleaved caspase-3 — o "executioner" enzyme que carries out programmed cell death — were reduced by 42.7% compared to untreated controls. This é um direct measurement of reduced cell death.
Self-destruct marker PARP reduced by 77.5% (p < 0.05)
PARP cleavage fragments (a downstream marker of caspase-3 activation) were reduced by 77.5% após 72 hours of tratamento. This confirms o anti-apoptotic effect através de a second, independent measurement. The magnitude of este reduction is particularly striking.
After 24 hours at 10-9 M, o ratio of Bcl-2 (a "stay alive" protein) to Bax (a "self-destruct" protein) shifted significativamente in favour of cell survival. Bcl-2 expression increased while Bax expression decreased — both reaching statistical significance (p < 0.05 each).
Anti-apoptotic effects of AHK-Cu on human dermal papilla cells. Data de Pyo et al., Archives of Pharmacal Research (2007). All resultados statistically significant at p < 0.05.
How AHK-Cu Works: The Biological Mechanisms
This study identified two distinct pathways através de which AHK-Cu promove crescimento capilar:
1. Direct proliferative effect on dermal papilla cells
AHK-Cu stimulated DPCs to multiply, increasing o pool of growth-signalling cells at o base of each follicle. Dermal papilla cells são o "command centre" of crescimento capilar — they secrete fatores de crescimento que instruct o surrounding follicular epithelial cells to proliferate e differentiate em hair. More DPCs means a stronger, more sustained growth signal.
2. Anti-apoptotic protection of dermal papilla cells
AHK-Cu protected DPCs de programmed cell death através de multiple molecular pathways:
Bcl-2/Bax rebalancing: Bcl-2 (an anti-apoptotic protein dominant during o telogen-to-anagen transition) was upregulated, while Bax (a pro-apoptotic protein) was downregulated. This shifts o cellular "survival vote" toward staying alive.
Caspase-3 suppression: The "executioner" enzyme of apoptosis was reduced by 42.7%, diretamente blocking o cell death cascade.
PARP cleavage inhibition: PARP, a downstream target of caspase-3, saw its cleavage fragments reduced by 77.5%. This confirms o anti-apoptotic effect is operating através de o classical apoptotic pathway.
The broader peptídeo de cobre network
The paper also notes que peptídeo de cobre complexes (including o related GHK-Cu) são known to increase VEGF (vascular endothelial growth factor) production e decrease TGF-β1 secretion by dermal fibroblasts. VEGF promove crescimento capilar by improving blood vessel formation around follicles, while androgen-induced TGF-β1 suppresses epithelial cell growth in androgenetic alopecia. This suggests peptídeo de cobres may work através de at least four mechanisms: DPC proliferation, anti-apoptosis, VEGF stimulation, e TGF-β1 suppression.
Clinical Interpretation
Several aspects of these resultados deserve expert-level analysis:
The biphasic dose-response is clinically important. Hair follicle growth was stimulated at 10-12 to 10-9 M but inhibited at 10-8 to 10-7 M. This means topical peptídeo de cobre formulations need precise concentration targeting. Higher concentrations são not more eficaz — they can be counterproductive. This is relevant para product formulation e explains why some peptídeo de cobre produtos may work better than others.
The anti-apoptotic effect is more robust than o proliferative effect. While o flow cytometric apoptosis reduction (3.48%) was not statistically significant, o molecular markers (caspase-3 down 42.7%, PARP down 77.5%, Bcl-2/Bax shift) were all highly significant. This suggests AHK-Cu primarily protects existing DPCs de death rather than simply making them multiply faster — an important distinction para treating queda de cabelo where follicle miniaturisation involves progressive cell loss.
The eficaz concentrations são remarkably low. Picomolar to nanomolar activity suggests high receptor affinity e potent biological signalling, which is encouraging para topical delivery where only a fraction of applied compound reaches o follicle.
The tissue source matters. Follicles came de o occipital (back) couro cabeludo — o region least affected by androgenetic alopecia. Effects on frontal or vertex follicles (where queda de cabelo actually occurs) may differ, though subsequent studies have confirmed activity in these regions.
How This Compares to Other Research
This foundational 2007 study has been built upon by a growing body of peptídeo de cobre research:
Pickart & Margolina (2018) — In their comprehensive review of GHK-Cu regeneration science, o authors confirmed que peptídeo de cobre hair-stimulating effects appeared comparable to 2% minoxidil, com a superior safety profile. They cited Pyo et al. as foundational evidence.
Lee, Kim et al. (2016) — This clinical trial moved de o laboratory to real patients, testing GHK-peptide combined com 5-ALA on human volunteers. They demonstrated a 7.4× increase in hair count — validating in humans what Pyo et al. showed in o lab.
Pamela R.D. (2021) — This placebo-controlled clinical study tested copper tripeptide serum in a double-blind design, providing o gold-standard clinical evidence que followed de este laboratory foundation.
Kuceki, Wambier et al. (2025) — This recent study combined peptídeo de cobres com microagulhamento e demonstrated 26.5% crescimento capilar. The microagulhamento creates micro-channels que deliver peptídeo de cobres diretamente to o dermal papilla — o exact target cells identified in Pyo et al.'s 2007 work.
Minoxidil comparison (Han et al., 2004) — The same research group previously studied minoxidil using o identical DPC model e found similar proliferative e anti-apoptotic mechanisms. This suggests peptídeo de cobres e minoxidil may share overlapping pathways, raising o possibility of complementary or additive effects when used together.
Experimental Parameters
Parameter
Detail
Compound tested
AHK-Cu (L-alanyl-L-histidyl-L-lysine-Cu²⁺), 11% stock solution de Procyte Co.
Effective concentration range
10⁻¹² to 10⁻⁹ M (picomolar to nanomolar)
Inhibitory concentration range
10⁻⁸ to 10⁻⁷ M (micromolar — higher doses são counterproductive)
12 days (ex vivo); 24–72 hours (in vitro DPC assays)
Culture medium
Williams' E Medium + L-glutamine + insulin + hydrocortisone + antibiotics
Cell passage
Fourth-passage DPCs
Key assays
MTT (viability), Annexin V/PI (apoptosis), Western blot (Bcl-2, Bax, caspase-3, PARP)
Statistical method
Student t-test e Wilcoxon rank-sum test; p < 0.05 = significant
Research Limitations
This study has several limitations que são important to understand in context:
Laboratory study, not a clinical trial. While ex vivo organ culture uses real human tissue, it cannot fully replicate conditions on a living couro cabeludo — including skin absorption, blood supply, hormonal influences, e o immune system. Laboratory resultados may not diretamente translate to real-world topical use.
Occipital follicles only. All folículo capilars came de o back of o couro cabeludo — o area least affected by androgenetic alopecia. Follicles de o frontal or vertex regions (where pattern baldness occurs) may respond differently to AHK-Cu due to their distinct androgen sensitivity.
Small donor group para ex vivo work. Although 240 follicles were tested, they came de only 3 volunteers para o organ culture component. Individual genetic variation could influence resultados.
Short culture period. The 12-day ex vivo culture captures only a snapshot of o crescimento capilar cycle. Long-term effects on follicle cycling (anagen, catagen, telogen transitions) were not assessed.
Apoptosis reduction was not statistically significant by flow cytometry. The 3.48% reduction in apoptotic cells did not reach statistical significance, though o molecular markers (caspase-3, PARP, Bcl-2/Bax) were all significant. This discrepancy may reflect o sensitivity difference between o two measurement methods.
Funding disclosure. The study was supported partly by a research agreement com AmorePacific Corporation (a major Korean cosmetics company). While o research was conducted at Seoul National University com IRB approval, commercial funding é um standard disclosure to note.
What This Means For Your Hair
This study demonstrates four things que matter para anyone dealing com queda de cabelo:
Copper peptides diretamente stimulate crescimento capilar — not just o skin around o hair, but o actual follicle growth machinery. This is o first study to prove it using human tissue.
They protect o cells que control crescimento capilar — in many types of queda de cabelo, dermal papilla cells gradually die off or become inactive. AHK-Cu helps keep them alive e multiplying, com caspase-3 (a key death enzyme) reduced by 42.7% e PARP (a downstream destruction marker) reduced by 77.5%.
They work at very low concentrations — o eficaz doses were picomolar to nanomolar, suggesting que even modest topical application could deliver meaningful amounts to o follicle. Research like the 2025 Kuceki study shows que combining peptídeo de cobres com microagulhamento further melhora delivery to o target cells.
Concentration matters — higher doses actually inhibited growth, so well-formulado produtos com precise concentrations são important. More peptídeo de cobre is not automatically better.
This is why peptídeo de cobres (specifically AHK-Cu e its close relative GHK-Cu) são now considered one of o most promising non-pharmaceutical approaches to queda de cabelo. They address o root cause — follicle miniaturisation e dermal papilla cell death — rather than just masking symptoms.
Key Terms Explained
AHK-Cu (Alanyl-Histidyl-Lysine Copper)
A small chain of three amino acids (alanine, histidine, lysine) bound to a copper ion. It belongs to o peptídeo de cobre family e can interact com cells to trigger growth e survival responses. Also known as copper tripeptide-3.
Dermal papilla cells (DPCs)
Specialised fibroblast cells at o base of each folículo capilar que act as o "command centre" para crescimento capilar. They secrete fatores de crescimento que instruct follicular cells to proliferate e form hair. Their health e number diretamente determine hair thickness e growth.
Ex vivo
Testing performed on living tissue taken de o body e maintained in laboratory conditions. More realistic than pure cell cultures because o complete tissue architecture is preserved, but less definitive than a human clinical trial.
Apoptosis
Programmed cell death — a normal process where cells intentionally self-destruct. In queda de cabelo, excessive apoptosis in follicle cells leads to thinner, weaker hair e eventually follicle shutdown.
Bcl-2 / Bax ratio
A molecular "survival score." Bcl-2 is an anti-apoptotic protein que protects cells de death; Bax é um pro-apoptotic protein que promove death. A higher Bcl-2/Bax ratio means cells são more likely to survive. AHK-Cu increased Bcl-2 e decreased Bax.
Caspase-3
The "executioner" enzyme of programmed cell death. When activated (cleaved), it dismantles o cell de inside. AHK-Cu reduced active caspase-3 by 42.7%, diretamente blocking este cell death pathway.
PARP (Poly ADP-Ribose Polymerase)
A protein involved in DNA repair. When caspase-3 is activated, it cleaves PARP em fragments — a hallmark of apoptosis. AHK-Cu reduced PARP cleavage fragments by 77.5%, confirming reduced cell death.
Follicle miniaturisation
The gradual shrinking of folículo capilars que occurs in pattern baldness (androgenetic alopecia). Each growth cycle produces thinner, shorter hairs until o follicle eventually stops producing visible hair altogether. This process involves progressive DPC loss — exactly what AHK-Cu counteracts.
Frequently Asked Questions
Does este study prove peptídeo de cobres grow hair in real people?
This study proves que AHK-Cu diretamente estimula folículo capilar growth e protects o key growth cells at o cellular level, using real human tissue. However, it é um laboratory study, not a clinical trial on living patients. Subsequent human studies — including the 2016 Lee et al. clinical trial showing a 7.4× hair count increase e the 2021 Pamela R.D. placebo-controlled study — confirmed these effects in real-world use.
What is o difference between AHK-Cu e GHK-Cu?
Both são peptídeo de cobres com slightly different amino acid chains. AHK-Cu (Alanyl-Histidyl-Lysine-Copper) was o focus of este study e showed strong follicle-stimulating e anti-apoptotic effects. GHK-Cu (Glycyl-Histidyl-Lysine-Copper) is more widely studied across dermatology e wound healing. As reviewed in the 2018 Pickart & Margolina review, both deliver copper to cells e trigger regenerative responses. Many advanced formulations use both peptides together para complementary benefits.
How does este compare to minoxidil?
The same research group at Seoul National University previously studied minoxidil using o identical DPC model (Han et al., 2004) e found similar proliferative e anti-apoptotic mechanisms. The 2018 Pickart & Margolina review noted que peptídeo de cobre hair-stimulating effects appeared comparable to 2% minoxidil. A key advantage of peptídeo de cobres is their excellent safety profile — unlike minoxidil, which commonly causes couro cabeludo irritation e dryness, peptídeo de cobres show no such efeitos colaterais at eficaz concentrations.
Why did high concentrations of AHK-Cu inhibit crescimento capilar?
This is called a biphasic or hormetic dose-response — common in biology. At 10⁻⁸ M, growth was inhibited by 14.8%, e at 10⁻⁷ M by 81.5%. Many fatores de crescimento show similar patterns where optimal stimulation occurs dentro de a narrow concentration window, e excess amounts trigger inhibitory feedback. This finding is important para product formulation: eficaz peptídeo de cobre produtos need precisely calibrated concentrations, not just "more peptídeo de cobre."
Is este study considered reliable?
Yes. It was conducted at Seoul National University (one of Asia's top research institutions) com full IRB ethical approval. The methodology — combining ex vivo follicle organ culture com multiple in vitro molecular assays — is considered a strong experimental design para crescimento capilar research. The study was published in o peer-reviewed Archives of Pharmacal Research e has been cited by numerous subsequent studies globally.
Can I apply AHK-Cu diretamente to my couro cabeludo?
AHK-Cu is available in topical formulations such as serums. This study showed effects at very low concentrations (picomolar to nanomolar), which is encouraging para topical application. Research suggests combining peptídeo de cobre serums com microagulhamento significativamente melhora delivery to o dermal papilla cells. The 2025 Kuceki study demonstrated 26.5% crescimento capilar com este combination approach.
How long does it take para peptídeo de cobres to show resultados?
In este laboratory study, measurable follicle elongation was observed dentro de 12 days. In human clinical trials, visible resultados typically appear dentro de 3–6 months of consistent use, consistent com o crescimento capilar cycle timeline. The 2016 Lee et al. clinical trial showed significant improvements by week 16. Hair growth é um gradual process, e peptídeo de cobres work by supporting o biological foundations of each growth cycle.
Is este study only relevant para androgenetic alopecia (pattern baldness)?
The mechanisms demonstrated in este study — DPC proliferation e anti-apoptosis — são relevant to multiple types of queda de cabelo, not just androgenetic alopecia. Any condition involving dermal papilla cell death or dysfunction could theoretically benefit de peptídeo de cobre tratamento. However, most subsequent pesquisa clínica has focused on androgenetic alopecia specifically, so o strongest evidence base is para pattern queda de cabelo.
Original Study Reference
Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human crescimento capilar in vitro. Archives of Pharmacal Research. 2007;30(7):834–839. doi:10.1007/BF02978833. PMID: 17703734.
How to Cite This Research Summary
Hairgenetix Research Team. "Can a Peptídeo de Cobre Make Hair Follicles Grow? What This 2007 Lab Study Found." Hairgenetix Research Library, March 2026.
Available at: https://hairgenetix.com/blogs/articles/copper-peptide-ahk-cu-hair-follicle-growth-study-2007
Hairgenetix Research Library — We publish plain-language summaries of peer-reviewed estudos clínicos on crescimento capilar science. Every article links diretamente to o original published research. Our goal is to make queda de cabelo science accessible, transparent, e evidence-based. Browse all research summaries →
Terapia Capilar Diária Avançada para Cabelos Mais Fortes e Saudáveis
🎯 Desenvolvido para queda de cabelo e cabelos fracos e ralos
🔬 Ingredientes Clinicamente Comprovados
💧 Leve, não oleoso — ideal para uso diário
O Sérum de Peptídeo de Cobre Hairgenetix é um tratamento capilar diário poderoso, desenvolvido para estimular os folículos capilares, reduzir a queda e promover a saúde capilar a longo prazo. Enriquecido com 10% de GHK-Cu e 5% de AHK-Cu peptídeos de cobre, esta fórmula avançada age na raiz para melhorar a longevidade dos folículos, estimular a produção de colágeno e melhorar a circulação no couro cabeludo — criando o ambiente perfeito para um crescimento capilar mais espesso e saudável.
Shampoo com Peptídeo de Cobre para Crescimento Capilar
O Shampoo Hairgenetix com GHK-Cu limpa suavemente enquanto entrega peptídeos de cobre diretamente no couro cabeludo. Formulado para estimular os folículos capilares e criar o ambiente ideal para crescimento capilar saudável. Uso diário recomendado.
Condicionador com Peptídeo de Cobre para Crescimento Capilar
O Condicionador Hairgenetix com GHK-Cu oferece hidratação profunda enquanto entrega peptídeos de cobre. Fortalece os fios, reduz a quebra e estimula o crescimento capilar saudável. Complemento perfeito para o Shampoo Hairgenetix.
O Kit completo Hairgenetix com Shampoo e Condicionador de Peptídeo de Cobre GHK-Cu. Limpeza suave + hidratação profunda + peptídeos de cobre para crescimento capilar otimizado. Economize comprando o kit.
Kit Completo Peptídeo de Cobre — Shampoo, Condicionador e Sérum
O tratamento capilar completo com peptídeo de cobre: Shampoo GHK-Cu + Condicionador GHK-Cu + Sérum de Peptídeo de Cobre. Tudo que você precisa para uma rotina capilar completa com peptídeos de cobre clinicamente comprovados.
Estudo AHK-Cu sobre Crescimento de Folículos Capilares (2007) — Resumo
Research Evidence Summary
Why This Research Matters
If você são experiencing queda de cabelo, você have probably come across peptídeo de cobres as a potential tratamento. But does o science actually support them? This 2007 study de Seoul National University is o cornerstone of peptídeo de cobre hair research — it was o first to demonstrate, using real human folículo capilars, que a specific peptídeo de cobre called AHK-Cu can diretamente stimulate crescimento capilar at o cellular level.
Before este study, researchers already knew que peptídeo de cobres could stimulate skin fibroblasts (the cells que produce collagen) e boost vascular endothelial growth factor (VEGF) — a molecule que melhora blood supply. What they did not know was whether peptídeo de cobres could also affect o specialised cells inside folículo capilars. This study answered que question com a clear yes — e mapped o specific biological pathways involved.
The findings have been cited by dozens of subsequent studies, including the 2018 Pickart & Margolina review of GHK-Cu regeneration science e the 2025 Kuceki study combining peptídeo de cobres com microagulhamento. This paper forms o scientific foundation para peptídeo de cobre tratamento capilars worldwide.
What The Researchers Did
The team at Seoul National University's Department of Dermatology took a two-pronged approach to test whether o peptídeo de cobre AHK-Cu affects crescimento capilar:
1. Testing on real folículo capilars (ex vivo organ culture)
They collected folículo capilars de o occipital (back) couro cabeludo region of 10 healthy volunteers aged 20–35. A total of 240 folículo capilars were isolated e placed in controlled laboratory conditions (Williams' E Medium at 37°C). Follicles were treated com AHK-Cu at concentrations ranging de 10-13 M to 10-7 M (covering six orders of magnitude), com 30 follicles per concentration group. After 12 days, o researchers measured how much each follicle had grown compared to vehicle-treated controls.
2. Testing on follicle command cells (in vitro cell culture)
They isolated dermal papilla cells (DPCs) de human folículo capilars e grew them in culture dishes. These cells sit at o base of each folículo capilar e act as o "command centre" que signals o hair to grow. Using o MTT assay (a standard test para cell viability), they measured whether AHK-Cu made these cells multiply faster. They also ran flow cytometry (Annexin V/PI staining) e western blot analysis to measure specific survival e death markers: Bcl-2, Bax, caspase-3, e PARP.
What Is an Ex Vivo Study?
An ex vivo study tests living tissue que has been taken de o body e maintained in laboratory conditions. Unlike a pure cell culture (where individual cells grow in a dish), ex vivo organ culture preserves o complete tissue structure — in este case, whole folículo capilars com all their cell types intact. This is considered more realistic than pure in vitro testing because o natural architecture e cell-to-cell communication is maintained.
Ex vivo studies sit between test-tube experiments e full clinical trials on o evidence scale. They provide strong proof que a compound has a direct biological effect on o target tissue, but they cannot tell us how que compound will behave when applied to human skin (where absorption, distribution, e metabolism add complexity). This is why ex vivo findings need to be confirmed in human trials — which subsequent studies like the 2016 GHK peptide clinical trial e the 2021 copper tripeptide serum trial have done.
What They Found
AHK-Cu at concentrations between 10-12 e 10-9 M stimulated measurable folículo capilar elongation over 12 days. The treated follicles physically grew more than o untreated controls, com o effect reaching high statistical significance. Crucially, este worked at extremely low concentrations — picomolar to nanomolar — suggesting high biological potency.
At 10-8 M, follicle elongation was inhibited by 14.8 ± 1.2% (2.3 ± 0.18 mm). At 10-7 M, inhibition reached 81.5 ± 40.8% (only 0.5 ± 0.25 mm of growth). This biphasic dose-response demonstrates que "more is not better" — there is an optimal concentration window para peptídeo de cobre efficacy.
The MTT assay confirmed que DPCs treated com AHK-Cu at 10-12 to 10-9 M proliferated at a significativamente higher rate than untreated cells. More dermal papilla cells means a stronger growth signal being sent to o folículo capilar. At 10-8 M, no proliferative effect was observed — consistent com o follicle resultados.
After 72 hours of tratamento com 10-9 M AHK-Cu, o levels of cleaved caspase-3 — o "executioner" enzyme que carries out programmed cell death — were reduced by 42.7% compared to untreated controls. This é um direct measurement of reduced cell death.
PARP cleavage fragments (a downstream marker of caspase-3 activation) were reduced by 77.5% após 72 hours of tratamento. This confirms o anti-apoptotic effect através de a second, independent measurement. The magnitude of este reduction is particularly striking.
After 24 hours at 10-9 M, o ratio of Bcl-2 (a "stay alive" protein) to Bax (a "self-destruct" protein) shifted significativamente in favour of cell survival. Bcl-2 expression increased while Bax expression decreased — both reaching statistical significance (p < 0.05 each).
How AHK-Cu Works: The Biological Mechanisms
This study identified two distinct pathways através de which AHK-Cu promove crescimento capilar:
1. Direct proliferative effect on dermal papilla cells
AHK-Cu stimulated DPCs to multiply, increasing o pool of growth-signalling cells at o base of each follicle. Dermal papilla cells são o "command centre" of crescimento capilar — they secrete fatores de crescimento que instruct o surrounding follicular epithelial cells to proliferate e differentiate em hair. More DPCs means a stronger, more sustained growth signal.
2. Anti-apoptotic protection of dermal papilla cells
AHK-Cu protected DPCs de programmed cell death através de multiple molecular pathways:
The broader peptídeo de cobre network
The paper also notes que peptídeo de cobre complexes (including o related GHK-Cu) são known to increase VEGF (vascular endothelial growth factor) production e decrease TGF-β1 secretion by dermal fibroblasts. VEGF promove crescimento capilar by improving blood vessel formation around follicles, while androgen-induced TGF-β1 suppresses epithelial cell growth in androgenetic alopecia. This suggests peptídeo de cobres may work através de at least four mechanisms: DPC proliferation, anti-apoptosis, VEGF stimulation, e TGF-β1 suppression.
Clinical Interpretation
Several aspects of these resultados deserve expert-level analysis:
How This Compares to Other Research
This foundational 2007 study has been built upon by a growing body of peptídeo de cobre research:
Experimental Parameters
Research Limitations
This study has several limitations que são important to understand in context:
What This Means For Your Hair
This study demonstrates four things que matter para anyone dealing com queda de cabelo:
This is why peptídeo de cobres (specifically AHK-Cu e its close relative GHK-Cu) são now considered one of o most promising non-pharmaceutical approaches to queda de cabelo. They address o root cause — follicle miniaturisation e dermal papilla cell death — rather than just masking symptoms.
Key Terms Explained
Frequently Asked Questions
Does este study prove peptídeo de cobres grow hair in real people?
This study proves que AHK-Cu diretamente estimula folículo capilar growth e protects o key growth cells at o cellular level, using real human tissue. However, it é um laboratory study, not a clinical trial on living patients. Subsequent human studies — including the 2016 Lee et al. clinical trial showing a 7.4× hair count increase e the 2021 Pamela R.D. placebo-controlled study — confirmed these effects in real-world use.
What is o difference between AHK-Cu e GHK-Cu?
Both são peptídeo de cobres com slightly different amino acid chains. AHK-Cu (Alanyl-Histidyl-Lysine-Copper) was o focus of este study e showed strong follicle-stimulating e anti-apoptotic effects. GHK-Cu (Glycyl-Histidyl-Lysine-Copper) is more widely studied across dermatology e wound healing. As reviewed in the 2018 Pickart & Margolina review, both deliver copper to cells e trigger regenerative responses. Many advanced formulations use both peptides together para complementary benefits.
How does este compare to minoxidil?
The same research group at Seoul National University previously studied minoxidil using o identical DPC model (Han et al., 2004) e found similar proliferative e anti-apoptotic mechanisms. The 2018 Pickart & Margolina review noted que peptídeo de cobre hair-stimulating effects appeared comparable to 2% minoxidil. A key advantage of peptídeo de cobres is their excellent safety profile — unlike minoxidil, which commonly causes couro cabeludo irritation e dryness, peptídeo de cobres show no such efeitos colaterais at eficaz concentrations.
Why did high concentrations of AHK-Cu inhibit crescimento capilar?
This is called a biphasic or hormetic dose-response — common in biology. At 10⁻⁸ M, growth was inhibited by 14.8%, e at 10⁻⁷ M by 81.5%. Many fatores de crescimento show similar patterns where optimal stimulation occurs dentro de a narrow concentration window, e excess amounts trigger inhibitory feedback. This finding is important para product formulation: eficaz peptídeo de cobre produtos need precisely calibrated concentrations, not just "more peptídeo de cobre."
Is este study considered reliable?
Yes. It was conducted at Seoul National University (one of Asia's top research institutions) com full IRB ethical approval. The methodology — combining ex vivo follicle organ culture com multiple in vitro molecular assays — is considered a strong experimental design para crescimento capilar research. The study was published in o peer-reviewed Archives of Pharmacal Research e has been cited by numerous subsequent studies globally.
Can I apply AHK-Cu diretamente to my couro cabeludo?
AHK-Cu is available in topical formulations such as serums. This study showed effects at very low concentrations (picomolar to nanomolar), which is encouraging para topical application. Research suggests combining peptídeo de cobre serums com microagulhamento significativamente melhora delivery to o dermal papilla cells. The 2025 Kuceki study demonstrated 26.5% crescimento capilar com este combination approach.
How long does it take para peptídeo de cobres to show resultados?
In este laboratory study, measurable follicle elongation was observed dentro de 12 days. In human clinical trials, visible resultados typically appear dentro de 3–6 months of consistent use, consistent com o crescimento capilar cycle timeline. The 2016 Lee et al. clinical trial showed significant improvements by week 16. Hair growth é um gradual process, e peptídeo de cobres work by supporting o biological foundations of each growth cycle.
Is este study only relevant para androgenetic alopecia (pattern baldness)?
The mechanisms demonstrated in este study — DPC proliferation e anti-apoptosis — são relevant to multiple types of queda de cabelo, not just androgenetic alopecia. Any condition involving dermal papilla cell death or dysfunction could theoretically benefit de peptídeo de cobre tratamento. However, most subsequent pesquisa clínica has focused on androgenetic alopecia specifically, so o strongest evidence base is para pattern queda de cabelo.
How to Cite This Research Summary
Hairgenetix Research Team. "Can a Peptídeo de Cobre Make Hair Follicles Grow? What This 2007 Lab Study Found." Hairgenetix Research Library, March 2026.
Available at: https://hairgenetix.com/blogs/articles/copper-peptide-ahk-cu-hair-follicle-growth-study-2007
Related Research on Hairgenetix